PlainPill

Guanfacine

Also known as Intuniv, Tenex

The short answer. More people than not who report on Guanfacine say it helped (71% of 50). It is most often used for focus: 85% of 26 reports say that improved. It is well studied — 53 meta-analyses on PubMed. The most common complaint is drowsiness.

What users report
71%helped50 reports · medium confidence
36 helped7 mixed7 didn't help

From 105 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
53
meta-analyses
116
RCTs
1,256
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Guanfacine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 53 meta-analyses on PubMed ↗ · 116 randomized trials ↗

Lancet Psychiatry · 2018 · Meta-analysis / systematic review
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.

PubMed 30097390 ↗
Mol Autism · 2022 · Meta-analysis / systematic review
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis

Conclusion: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.

PubMed 35246237 ↗
Lancet Psychiatry · 2025 · Meta-analysis / systematic review
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis

Conclusion: Stimulants and atomoxetine were the only interventions with evidence of beneficial effects in terms of reducing ADHD core symptoms in the short term, supported by both self-reported and clinician-reported ratings. However, atomoxetine was less acceptable than placebo. Medications for ADHD were not efficacious on additional relevant outcomes, such as quality of life, and evidence in the longer term is underinvestigated. The effects of non-pharmacological strategies were inconsistent across different raters. Our network meta-analysis represents the most comprehensive synthesis of available evide

PubMed 39701638 ↗
PLoS One · 2020 · Meta-analysis / systematic review
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis

Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu

PubMed 33085721 ↗
Registered clinical trials

97 human trials on ClinicalTrials.gov test Guanfacine — 67 completed, 10 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

The current US prescription label has no boxed warning.

Full label on DailyMed (NIH) ↗

FDA recalls

4 recalls of products named for Guanfacine. Most recent:

  • 2021-04-14 · Class II: Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate record ↗
  • 2014-01-29 · Class II: Labeling: Label Mixup: guanFACINE HCl, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: buPROPion HCl ER, Tablet, 200 mg,… record ↗
  • 2014-01-29 · Class II: Labeling: Label Mixup: guanFACINE HC, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: glyBURIDE, Tablet, 2.5 mg, NDC… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

7,823 adverse-event reports mention Guanfacine. Most often reported:

  • Drug ineffective · 813
  • Off label use · 630
  • Somnolence · 471
  • Aggression · 388
  • Fatigue · 351
  • Hypotension · 299

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Guanfacine E — an unlikely cause of liver injury. LiverTox entry ↗

US government research funding (NIH)

NIH has funded 21 research projects with Guanfacine in the title, $18,586,928 in total (1985–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Guanfacine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

drowsiness ×6fatigue ×2shaky hands ×1dry mouth ×1hair loss ×1low blood ×1emotional dampening ×1hypertensive crisis ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“It helped so much with rejection sensitivity. I felt braver. Guanfacine is an alpha agonist and decreases norepinephrine/fight and flight response. It takes 3 weeks to kick in and you need to take this every day.”
HelpedRead the discussion ↗
“I'm on guanfacine after taking stimulants. It's….. better than taking nothing but guanfacine is like a 2 out of 10.”
Didn't helpRead the discussion ↗
“Currently i am taking clomipramine and guanfacine which helps for the anxiety and dpdr but makes me sleepy all day.”
MixedRead the discussion ↗
“I've tried the traditional ADHD meds like Strattera and Guanfacine, and they don't offer any improvement.”
Didn't helpRead the discussion ↗
Read more Guanfacine reviews →
Top discussions (5)

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate